Spondyloarthritis & psoriatic arthritis
Comparing DAPSA, DAPSA28, and DAS28‐CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries
Authors' conclusion
In patients with PsA, DAPSA28 should be preferred over DAS28-CRP as a substitute for DAPSA when 66/68 joint counts are not available because of the large overlap in remission and response status and in predictors between DAPSA and DAPSA28.
Study context
- Population
- European bionaive patients with psoriatic arthritis (PsA) initiating a first TNFiremission cohort
- Participants
- 3,159 patients
- Exposure
- DAPSA28 vs disease activity score with C-reactive protein (DAS28-CRP) as substitutes for DAPSA
- Outcome
- Remission and response status by DAPSA, DAPSA28 and DAS28-CRP
- Follow-up
- 6 months
Methodological detailspooled real-world data, nine European countries, logistic regression on multiple imputed data
- Pooled real-world data
- Nine European countries
- Logistic regression on multiple imputed data
Main finding
As reported in the abstract
Remission/response
Remission/response · 6 months
Response
Observational data: associations, not effects.
Further findings
Baseline predictors of remission and response (of 14 possible baseline predictors) · 6 months
- Predicted both DAPSA and DAPSA28 remission
- 11
- Of these, also predicted DAPSA and DAPSA28 response
- 8
- Of these, predicted DAS28-CRP remission
- Eight
- Of these, predicted DAS28-CRP response
- five
- Positive predictors: longer disease duration*, male sex*, higher CRP* (* also predicted response)
- Negative predictors: older age*, higher BMI*, patient fatigue*, patient global, physician global, HAQ score*, tender and swollen* joint counts (* also predicted response)
- Logistic regression on multiple imputed data
Original publication
Comparing DAPSA, DAPSA28, and DAS28‐CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries. Arthritis Care Res (Hoboken). Published 19 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →